LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Geschlossen

1.18 -1.67

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.15

Max

1.2

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.7M -24M
EPS	-0.354
Angestellte	49
EBITDA	-5.3M -28M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+122.5% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	14. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-7.4M 74M
Vorheriger Eröffnungskurs	2.85
Vorheriger Schlusskurs	1.18

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Mai 2026, 22:50 UTC

Ergebnisse

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12. Mai 2026, 22:49 UTC

Ergebnisse

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12. Mai 2026, 22:32 UTC

Ergebnisse

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12. Mai 2026, 23:48 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12. Mai 2026, 22:57 UTC

Market Talk

Ergebnisse

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12. Mai 2026, 22:26 UTC

Ergebnisse

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12. Mai 2026, 22:25 UTC

Ergebnisse

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12. Mai 2026, 22:25 UTC

Ergebnisse

Aristocrat Leisure Interim Dividend A$0.50/Security

12. Mai 2026, 22:24 UTC

Ergebnisse

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12. Mai 2026, 22:23 UTC

Ergebnisse

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12. Mai 2026, 22:23 UTC

Ergebnisse

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12. Mai 2026, 22:19 UTC

Ergebnisse

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12. Mai 2026, 22:14 UTC

Ergebnisse

CBA: Business Lending Continued to Grow Above System>CBA.AU

12. Mai 2026, 22:14 UTC

Ergebnisse

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12. Mai 2026, 22:13 UTC

Ergebnisse

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12. Mai 2026, 22:12 UTC

Ergebnisse

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12. Mai 2026, 22:12 UTC

Ergebnisse

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12. Mai 2026, 22:11 UTC

Ergebnisse

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12. Mai 2026, 22:11 UTC

Ergebnisse

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12. Mai 2026, 22:10 UTC

Ergebnisse

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12. Mai 2026, 22:09 UTC

Ergebnisse

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12. Mai 2026, 22:09 UTC

Ergebnisse

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12. Mai 2026, 22:08 UTC

Ergebnisse

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12. Mai 2026, 22:07 UTC

Ergebnisse

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12. Mai 2026, 22:06 UTC

Ergebnisse

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12. Mai 2026, 22:06 UTC

Ergebnisse

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12. Mai 2026, 22:05 UTC

Ergebnisse

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12. Mai 2026, 22:04 UTC

Ergebnisse

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12. Mai 2026, 22:04 UTC

Ergebnisse

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12. Mai 2026, 22:04 UTC

Ergebnisse

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

122.5% Vorteil

12-Monats-Prognose

Durchschnitt 2.67 USD 122.5%

Hoch 3 USD

Tief 2 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.